Publications by authors named "Marc Alfonsi"

Claim this Profile
A
A GORTEC survey on low-risk CTV-P2 delineation in head and neck cancers.
Michel Lapeyre, Yoann Pointreau, Marc Alfonsi, Pierre Boisselier, Julian Biau

Clin Transl Radiat Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard versus fractionated high-dose cisplatin plus radiation for locally advanced head and neck cancer: Results of the CisFRad (GORTEC 2015-02) randomized phase II trial.
Christian Borel, Xu-Shan Sun, Alexandre Coutte, Guillaume Bera, Christian Sire, Marc Alfonsi

Radiother Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain radiotherapy in patients treated for a newly diagnosed primary central nervous system lymphoma: professional practice evaluation in 19 French centers.
Alice Thomas-Joulié, Caroline Houillier, Delphine Antoni, Gilles Créhange, Emmanuel Jouglar, Marc Alfonsi

Acta Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Yungan Tao, Xu-Shan Sun, Yoann Pointreau, Christophe Le Tourneau, Christian Sire, Marc Alfonsi

Eur J Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).
Séverine Racadot, Isabelle Thennevet, Yaelle Ouldbey, Marie-Christine Kaminsky, Mathieu Bosset, Marc Alfonsi

Eur J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT.
Joël Guigay, Emmanuel Chamorey, Gautier Lefebvre, Maciej Rotarski, Jean-Philippe Wagner, Marc Alfonsi

Cancer Rep (Hoboken)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
Thomas Chevalier, Amaury Daste, Esmaa Saada-Bouzid, Anderson Loundou, Florent Peyraud, Marc Alfonsi

Cancer Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind phase III trial of immunomodulating nutritional formula during adjuvant chemoradiotherapy in head and neck cancer patients: IMPATOX.
Pierre Boisselier, Marie-Christine Kaminsky, Simon Thézenas, Olivier Gallocher, Sandrine Lavau-Denes, Marc Alfonsi

Am J Clin Nutr· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpretable Machine Learning Model for Locoregional Relapse Prediction in Oropharyngeal Cancers.
Paul Giraud, Philippe Giraud, Eliot Nicolas, Pierre Boisselier, Marc Alfonsi

Cancers (Basel)· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
Yungan Tao, Anne Auperin, Pierre Blanchard, Marc Alfonsi, Xu-Shan Sun

Radiother Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Xu-Shan Sun, Yungan Tao, Christophe Le Tourneau, Yoann Pointreau, Christian Sire, Marc Alfonsi

Lancet Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial.
Guillaume Janoray, Yoann Pointreau, Marc Alfonsi, Christian Sire, Lionel Geoffrois

Eur J Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study.
Renaud Garrel, Martine Mazel, Françoise Perriard, Marie Vinches, Laure Cayrefourcq, Marc Alfonsi

Clin Chem· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Félicien Le Louedec, Catherine Alix-Panabières, Thierry Lafont, Ben C Allal, Renaud Garrel, Marc Alfonsi

Br J Clin Pharmacol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.
Lionnel Geoffrois, Laurent Martin, Dominique De Raucourt, Xu Shan Sun, Yungan Tao, Marc Alfonsi

J Clin Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.
Yungan Tao, Anne Auperin, Christian Sire, Laurent Martin, Cedric Khoury, Marc Alfonsi

J Clin Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score-Weighted Analysis.
Jean-Emmanuel Bibault, Sophie Dussart, Pascal Pommier, Magali Morelle, Marius Huguet, Marc Alfonsi

Int J Radiat Oncol Biol Phys· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Yungan Tao, Anne Aupérin, Pierre Graff, Michel Lapeyre, Vincent Grégoire, Marc Alfonsi

Oral Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost Analysis of Complex Radiation Therapy for Patients With Head and Neck Cancer.
Lionel Perrier, Magali Morelle, Pascal Pommier, Pierre Boisselier, Bernard Coche-Dequeant, Marc Alfonsi

Int J Radiat Oncol Biol Phys· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Guillaume Janoray, Yoann Pointreau, Pascal Garaud, Sophie Chapet, Marc Alfonsi

J Natl Cancer Inst· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.
Jean Louis Lefebvre, Yoann Pointreau, Frederic Rolland, Marc Alfonsi, Alain Baudoux

J Clin Oncol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03.
Ivan Toledano, Pierre Graff, Antoine Serre, Pierre Boisselier, René-Jean Bensadoun, Marc Alfonsi

Radiother Oncol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Jean Bourhis, Christian Sire, Pierre Graff, Vincent Grégoire, Philippe Maingon, Marc Alfonsi

Lancet Oncol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial.
Michael Henke, Marc Alfonsi, Paolo Foa, Jordi Giralt, Etienne Bardet

J Clin Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial.
Etienne Bardet, Laurent Martin, Gilles Calais, Marc Alfonsi, Nasr Eddine Feham

J Clin Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis